Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

Cross-reactivity

Cross-reactivity

Antibody Structure

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

Humoral Immune Responses

Humoral Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Complement activation profile in adult primary immune thrombocytopenia.

Blood·2026

Same author

Endothelial semaphorin 6D controls immune responses under cold stress through regulation of sympathetic innervation.

Journal of immunology (Baltimore, Md. : 1950)·2026

Same author

Single-cell analysis reveals immune cell abnormalities underlying the clinical heterogeneity of patients with systemic sclerosis.

Nature communications·2025

Same author

Neutrophil single-cell analysis identifies a type II interferon-related subset for predicting relapse of autoimmune small vessel vasculitis.

Nature communications·2025

Same author

Human social behavior and oxytocin: Molecular and neuronal mechanisms.

Neuroscience·2025

Same author

Arginine: A potential prophylactic supplement for transthyretin amyloidosis.

Biochemical and biophysical research communications·2024

Same journal

Author Correction: Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy.

Nature biotechnology·2026

Same journal

Quantum computing in transition.

Nature biotechnology·2026

Same journal

Author Correction: Improved RNA base editing with guide RNAs mimicking highly edited endogenous ADAR substrates.

Nature biotechnology·2026

Same journal

Unlocking the chemical potential of filamentous fungi using prime editing.

Nature biotechnology·2026

Same journal

A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.

Nature biotechnology·2026

Same journal

Prime editing for precise genome engineering and modulation of fungal metabolism.

Nature biotechnology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle

Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle

Published on: July 11, 2015

Antigen-specific human polyclonal antibodies from hyperimmunized cattle.

Yoshimi Kuroiwa¹, Poothappillai Kasinathan, Thillainayagen Sathiyaseelan

¹Hematech, Inc, 4401 S. Technology Dr., Sioux Falls, South Dakota 57106, USA. ykuroiwa@hematech.com

Nature Biotechnology

|January 20, 2009

Summary

This summary is machine-generated.

Transchromosomic (Tc) cattle were engineered to produce high yields of therapeutic human polyclonal antibodies (hpAbs). This novel bovine system overcomes previous low-yield limitations for hpAb production, enabling potential new treatments for human diseases.

More Related Videos

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Immunization of Alpacas (Lama pacos) with Protein Antigens and Production of Antigen-specific Single Domain Antibodies

Immunization of Alpacas (Lama pacos) with Protein Antigens and Production of Antigen-specific Single Domain Antibodies

Published on: January 26, 2019

Related Experiment Videos

Last Updated: Jun 26, 2026

Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle

Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle

Published on: July 11, 2015

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Immunization of Alpacas (Lama pacos) with Protein Antigens and Production of Antigen-specific Single Domain Antibodies

Immunization of Alpacas (Lama pacos) with Protein Antigens and Production of Antigen-specific Single Domain Antibodies

Published on: January 26, 2019

Area of Science:

Immunology
Biotechnology
Genetics

Background:

Human polyclonal antibodies (hpAbs) show therapeutic potential for various diseases.
Existing transgenic and transchromosomic (Tc) systems in mice and cattle yield insufficient hpAbs for clinical use.

Purpose of the Study:

To develop a Tc bovine system capable of producing large yields of hpAbs.

Main Methods:

Generated Tc cattle by transferring human immunoglobulin heavy (hIGH) and kappa-light (hIGK) loci on an artificial chromosome into bovine fibroblasts with inactivated endogenous IgH loci.
Hyperimmunized Tc cattle with anthrax protective antigen.

Main Results:

The Tc bovine system produced high yields of human IgG (hIgG) (>2 g/l).
The produced hIgG was paired with human kappa-light chains (fully human) or bovine kappa/lambda-light chains (chimeric), maintaining normal IgG subclass distribution.
Hyperimmunization elicited a strong antigen-specific hIgG response.
Purified human and chimeric hIgGs demonstrated high activity in in vitro toxin neutralization and in vivo protection assays.

Conclusions:

The Tc bovine system successfully generates large quantities of therapeutic-grade hpAbs.
This system offers a viable solution for overcoming low-yield limitations in hpAb production.
The produced hpAbs are effective in neutralizing toxins and providing in vivo protection, indicating therapeutic promise.